RAF1 and plasma cell myeloma: In the present study, we demonstrate that TAS-116 in combination with an inhibitor of the RAS-RAF-MEK-ERK signaling pathway shows significant synergistic anti-myeloma effects in RAS- or BRAF-mutated MM cell lines in vitro, providing the framework for its clinical evaluation to improve MM patient outcome.